Fidelity Investments
ADCT icon

Fidelity Investments’s ADC Therapeutics ADCT Stock Holding History

Fidelity Investments’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$142K Sell
132,775
-39,903
-23% -$116K ﹤0.01% 3818
2026
Q1 		$648K Buy
172,678
+38,881
+29% +$153K ﹤0.01% 3019
2025
Q4 		$472K Buy
133,797
+370
+0.3% +$1.5K ﹤0.01% 3107
2025
Q3 		$534K Buy
133,427
+1,562
+1% +$4.92K ﹤0.01% 3006
2025
Q2 		$353K Sell
131,865
-4,551
-3% -$9.57K ﹤0.01% 3103
2025
Q1 		$192K Buy
136,416
+9,397
+7% +$16K ﹤0.01% 3264
2024
Q4 		$253K Buy
127,019
+73,977
+139% +$194K ﹤0.01% 3178
2024
Q3 		$167K Buy
+53,042
New +$167K ﹤0.01% 3260
2024
Q1 		– Sell
-6
Closed -$10 – 5342
2023
Q4 		$10 Sell
6
-1,309
-100% -$1.21K ﹤0.01% 5314
2023
Q3 		$1.18K Sell
1,315
-67
-5% -$89 ﹤0.01% 4630
2023
Q2 		$2.97K Sell
1,382
-39,062
-97% -$87.8K ﹤0.01% 4499
2023
Q1 		$78.9K Sell
40,444
-4,613,009
-99% -$17M ﹤0.01% 3276
2022
Q4 		$17.9M Sell
4,653,453
-3,019,684
-39% -$12.1M ﹤0.01% 1657
2022
Q3 		$37M Sell
7,673,137
-7,909
-0.1% -$57.3K ﹤0.01% 1366
2022
Q2 		$61.1M Hold
7,681,046
– – 0.01% 1174
2022
Q1 		$113M Buy
7,681,046
+8,373
+0.1% +$133K 0.01% 1022
2021
Q4 		$155M Hold
7,672,673
– – 0.01% 901
2021
Q3 		$208M Hold
7,672,673
– – 0.02% 791
2021
Q2 		$187M Sell
7,672,673
-88,912
-1% -$2.06M 0.01% 856
2021
Q1 		$189M Hold
7,761,585
– – 0.02% 812
2020
Q4 		$248M Buy
7,761,585
+90,000
+1% +$2.95M 0.02% 662
2020
Q3 		$253M Buy
7,671,585
+2,427,354
+46% +$105M 0.03% 548
2020
Q2 		$245M Buy
+5,244,231
New +$199M 0.03% 525

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fidelity Investments's ADCT Position: Q2 2026 in Review

Fidelity Investments reduced its ADC Therapeutics (ADCT) stake by 23% in Q2 2026, selling an estimated $116K and leaving 132,775 shares worth $142K. The position accounts for ﹤0.01% of the portfolio, ranked #3818.

Fidelity Investments first reported a position in ADCT in Q2 2020 and has held it in 23 quarters since. The position peaked at $253M in Q3 2020. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Fidelity Investments held 132,775 shares of ADC Therapeutics worth $142K as of Q2 2026.
  • Fidelity Investments sold 39,903 ADC Therapeutics shares in Q2 2026, an estimated $116K.
  • ADC Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #3818 holding.
  • Fidelity Investments first reported a position in ADC Therapeutics in Q2 2020 and has held it in 23 quarters since.
  • Fidelity Investments's ADC Therapeutics position peaked at $253M in Q3 2020.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.